Diao Yuchao, Jiao Jinwen, Song Kejuan, Wang Lei, Lv Teng, Dai Shuzhen, Yao Qin
Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Mol Clin Oncol. 2017 Sep;7(3):395-398. doi: 10.3892/mco.2017.1328. Epub 2017 Jul 18.
Vaginal cancer is a rare gynecological malignancy, mainly treated by radiotherapy and surgery. However, the effect of neoadjuvant chemotherapy on patients with vaginal cancer has not been extensively evaluated. The aim of the present study was to assess the feasibility and efficacy of irinotecan and cisplatin in the management of patients with vaginal squamous cell cancer (SCC). Two patients with International Federation of Obstetrics and Gynecology (FIGO) stage I and one patient with FIGO stage II vaginal SCC were treated with irinotecan (240 mg) and cisplatin (100 mg) every 3-4 weeks. The effect of chemotherapy after 2-4 courses was assessed and the next step of treatment was determined according to the outcome. In the present study, all 3 patients had complete remission after 2-4 courses of chemotherapy. In case 1, the patient received a total of 6 courses of chemotherapy and had no recurrence after 45 months of follow-up. In case 2, the patient received 4 courses of chemotherapy and partial vaginal resection, and had no recurrence after 48 months of follow-up. In case 3, the patient underwent laparoscopic radical surgery and peritoneal vaginoplasty after 2 courses of chemotherapy, and no residual tumors were identified in the resected tissues on postoperative pathological examination. Effective neoadjuvant chemotherapy may decrease the size of the tumor, induce tumor regression, or even achieve pathologically-confirmed complete tumor eradication. Thus, neoadjuvant chemotherapy with irinotecan combined with cisplatin is a feasible treatment for patients with early-stage vaginal SCC. In the present study, all the patients achieved good therapeutic results following chemotherapy.
阴道癌是一种罕见的妇科恶性肿瘤，主要通过放疗和手术治疗。然而，新辅助化疗对阴道癌患者的疗效尚未得到广泛评估。本研究的目的是评估伊立替康和顺铂治疗阴道鳞状细胞癌（SCC）患者的可行性和疗效。3例国际妇产科联盟（FIGO）I期阴道SCC患者和1例FIGO II期阴道SCC患者接受伊立替康（240 mg）和顺铂（100 mg）治疗，每3 - 4周一次。评估2 - 4个疗程化疗后的效果，并根据结果确定下一步治疗方案。在本研究中，所有3例患者在2 - 4个疗程化疗后均完全缓解。病例1中，患者共接受6个疗程化疗，随访45个月后无复发。病例2中，患者接受4个疗程化疗及部分阴道切除术，随访48个月后无复发。病例3中，患者在2个疗程化疗后接受腹腔镜根治性手术及腹膜阴道成形术，术后病理检查切除组织中未发现残留肿瘤。有效的新辅助化疗可能会减小肿瘤大小，诱导肿瘤消退，甚至实现经病理证实的肿瘤完全根除。因此，伊立替康联合顺铂的新辅助化疗对早期阴道SCC患者是一种可行的治疗方法。在本研究中，所有患者化疗后均取得了良好的治疗效果。
